A. Naves

Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.

E. Ocio, L. Rosiñol, R. Ríos, 2021, Clinical lymphoma, myeloma & leukemia.

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

J. Mas, Guillem Jorba, C. Segú-Vergés, 2021, Oncotarget.

Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish Real‐T study

F. Climent, J. Castellví, M. Fraga, 2023, British journal of haematology.

Real-World Health Care Services Utilization Associated with the Management of Patients with Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study

E. Ocio, L. Rosiñol, V. González-Calle, 2023, Clinical Lymphoma Myeloma and Leukemia.

Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study

A. Mayol, V. González-Calle, M. Grande, 2023, Leukemia & lymphoma.